Bengt Hallberg

University of Gothenburg — Sweden

Medicine · Health Sciences

49h-index7.4kcitations206works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(105), Cancer, Hypoxia, and Metabolism(38), Cancer therapeutics and mechanisms(32), Lung Cancer Research Studies(30), Neuroendocrine Tumor Research Advances(23)

Publications206 total

ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN
2025· 1 citedOpen Access
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2025Open Access
RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastoma
2024Open Access
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure 5 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure 4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
Figure 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
2024Open Access
page 1 of 11Next →

Frequent Co-authors

Ruth H. Palmer(29), Kristina Ruuth(9), Ganesh Umapathy(8), Tommy Martinsson(8), Christina Schönherr(7), Jikui Guan(6), Damini Chand(5), Per Kogner(5), Julian Downward(4), Thomas Grundström(4), Maria L. Henriksson(4), Yasuo Yamazaki(4), Anna Djos(4), Susanne Fransson(4), Jimmy Van den Eynden(4), Joachim T. Siaw(4), Caroline Grabbe(3), Louis Chesler(3), Anders Thornell(3), Patricia Mendoza-García(3)